OB Pharmaceuticals was formed in 2012 to undertake the research and development of a new molecule that shows promise for the treatment of Epilepsy.
Epilepsy is a chronic neurological disorder characterized by recurrent and often debilitating seizures.
A seizure is abnormal (excessive) electrical activity of the brain that results in some sort of impairment such as the loss of consciousness and / or involuntary muscle movements.

Our Drug Pipeline

OB Pharmaceuticals has developed a new class of medications (oxynytones) that act at a unique target in the brain to prevent electrical activity that leads to seizures. Our medications not only stop seizures from occurring in epileptic brains but also prevent epilepsy from occurring in the first place. This activity combined with low or no side effects makes oxynytones one of the most promising new preclinical medications currently under development.

Latest from the Blog